North America Human Papillomavirus (HPV) Vaccine Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (9-Valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-Based Health Centers, Health Departments, Hospitals, and Others)

No. of Pages: 127    |    Report Code: BMIRE00026304    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Human Papillomavirus (HPV) Vaccine Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Human Papillomavirus (HPV) Vaccine Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Rising awareness about cervical cancer prevention
  • 5.1.2 Government vaccination programs
  • 5.1.3 Growth in global healthcare access
5.2 Market Opportunities
  • 5.2.1 Expansion in developing countries
  • 5.2.2 Introduction of new vaccine formulations
  • 5.2.3 Increased funding for immunization programs
5.3 Future Trends
  • 5.3.1 Development of multi-strain vaccines
  • 5.3.2 Increasing global vaccination coverage
  • 5.3.3 Focus on adolescent immunization programs
5.4 Impact of Drivers and Restraints

6. North America Human Papillomavirus (HPV) Vaccine Market Regional Analysis

6.1 North America Human Papillomavirus (HPV) Vaccine Market Overview
6.2 North America Human Papillomavirus (HPV) Vaccine Market Revenue 2020-2028 (US$ Million)
6.3 North America Human Papillomavirus (HPV) Vaccine Market Forecast Analysis

7. North America Human Papillomavirus (HPV) Vaccine Market Analysis – by Type

7.1 9-Valent HPV Vaccine
  • 7.1.1 Overview
  • 7.1.2 9-Valent HPV Vaccine: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Quadrivalent HPV Vaccine
  • 7.2.1 Overview
  • 7.2.2 Quadrivalent HPV Vaccine: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Bivalent HPV Vaccine
  • 7.3.1 Overview
  • 7.3.2 Bivalent HPV Vaccine: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Human Papillomavirus (HPV) Vaccine Market Analysis – by Dosage

8.1 2 Dose and 3 Dose
  • 8.1.1 Overview
  • 8.1.2 2 Dose and 3 Dose: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Human Papillomavirus (HPV) Vaccine Market Analysis – by Age

9.1 9 to 14 Years and 15 to 45 Years
  • 9.1.1 Overview
  • 9.1.2 2 Dose and 3 Dose: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Human Papillomavirus (HPV) Vaccine Market – North America Analysis

10.1 North America
  • 10.1.1 North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 US: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 10.1.1.1.2 US: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 10.1.1.1.3 US: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
  • 10.1.1.2 Canada: North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Canada: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 10.1.1.2.2 Canada: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 10.1.1.2.3 Canada: North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
  • 10.1.1.3 Mexico : North America Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 10.1.1.3.2 Mexico : North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 10.1.1.3.3 Mexico : North America Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Human Papillomavirus (HPV) Vaccine Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 ChengDu Institute of Biological Products Co., Ltd.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Inovio Pharmaceuticals
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Merck & Co., Inc.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 R-Pharm
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Sanofi
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Serum Institute of India Pvt. Ltd
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Vaccitech
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Walvax Biotechnology Co., Ltd.
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

  1. ChengDu Institute of Biological Products Co., Ltd.
  2. GlaxoSmithKline plc.
  3. Inovio Pharmaceuticals
  4. Merck & Co., Inc.
  5. R-Pharm
  6. Sanofi
  7. Serum Institute of India Pvt. Ltd
  8. Vaccitech  
  9. Walvax Biotechnology Co., Ltd.
north-america-human-papillomavirus-hpv-vaccine-market